Cost-utility of cognitive behavioral therapy versus U.S. Food and Drug Administration recommended drugs and usual care in the treatment of patients with fibromyalgia: an economic evaluation alongside a 6-month randomized controlled trial

INTRODUCTION: Cognitive behavioral therapy (CBT) and U.S. Food and Drug Administration (FDA)-recommended pharmacologic treatments (RPTs; pregabalin, duloxetine, and milnacipran) are effective treatment options for fibromyalgia (FM) syndrome and are currently recommended by clinical guidelines. We co...

Descripción completa

Detalles Bibliográficos
Autores principales: Luciano, Juan V, D’Amico, Francesco, Cerdà-Lafont, Marta, Peñarrubia-María, María T, Knapp, Martin, Cuesta-Vargas, Antonio I, Serrano-Blanco, Antoni, García-Campayo, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203881/
https://www.ncbi.nlm.nih.gov/pubmed/25270426
http://dx.doi.org/10.1186/s13075-014-0451-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203881/
https://www.ncbi.nlm.nih.gov/pubmed/25270426
http://dx.doi.org/10.1186/s13075-014-0451-y

Ejemplares similares